English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Over the last few years, there is tremendous growth of melanoma skin cancer in all around the world. Paclitaxel is an antineoplastic drug which is widely used for breast cancer, lung cancer, and Kaposi sarcoma. It is available only in the form of intravenous (IV), which produces tissue damage and hypersensitivity in some patients if the dose is over. In the present article, the new initiative formulation is done for melanoma skin cancer with transfersomes drug delivery systems. A different formulation of transfersomes is prepared using Span. The various characterization is done for the transfersomes like morphology, entrapment ef icacy, in vitro drug release dialysis bag method. By using the Carbopol 940, the transfersomes gel was prepared. Paclitaxelloaded transfersomes (FS-2) shows the positive entrapment ef icacy 68.2% and the vesicle size 200 nm. From the in vitro dialysis bag method, FS-2 showed the high rate of drug release by nearly 72% in 12 hrs. we conclude that this will be the initial step for the further studies of melanoma skin cancer and provide the better treatment for skin cancer.

Paclitaxel loaded transfersomal vesicular drug delivery for the treatment of melanoma skin cancers